SVR-12 Laboratory Assessment
The SVR-12 assessment consists of a single laboratory test: HCV RNA measurement using a sensitive assay with a lower limit of detection <50 IU/mL, performed 12 weeks after completion of hepatitis C treatment.
Core Laboratory Test
- HCV RNA quantitative assay is the essential and only required test for SVR-12 determination 1
- The assay must have a lower limit of detection ≤50 IU/mL to accurately define sustained virologic response 1, 2
- Undetectable HCV RNA at 12 weeks post-treatment defines SVR-12 and is considered equivalent to the traditional SVR-24 (24 weeks post-treatment) 1, 3
Clinical Context and Validation
The shift from SVR-24 to SVR-12 as the primary endpoint occurred because:
- SVR-12 has a positive predictive value of 99.7% for predicting SVR-24, making the 12-week timepoint highly reliable 3
- Modern clinical trials for direct-acting antivirals routinely use SVR-12 as the therapeutic efficacy endpoint 1
- SVR-12 is tantamount to virologic cure, with fewer than 1% of patients experiencing late relapse after achieving SVR-12 4
Additional Laboratory Considerations
While not part of the SVR-12 definition itself, guidelines recommend:
- Hepatic aminotransferase testing (ALT/AST) at the same 12-week post-treatment timepoint to assess liver function 5
- For patients with advanced fibrosis or cirrhosis, ongoing surveillance for hepatocellular carcinoma with imaging ± AFP should continue indefinitely despite achieving SVR 4, 5
- No routine HCV RNA testing beyond SVR-12 is needed unless the patient has ongoing risk factors for reinfection or unexplained hepatic dysfunction 6, 4
Important Caveats
- Some newer data suggest SVR-4 (4 weeks post-treatment) may have sufficient predictive value (>99% PPV) for SVR-12 in patients treated with pangenotypic direct-acting antivirals, though this is not yet standard practice 7, 8, 9
- The traditional definition requiring undetectable HCV RNA at 24 weeks post-treatment remains valid but is no longer necessary for routine clinical practice 1